Michael Aberman is a Pioneer at Artis Ventures. He previously served as the SVP of Strategy and Investor Relations at Regeneron Pharmaceuticals, and the CEO of Quentis Therapeutics.

 

As a Pioneer, Michael brings over a decade of pharma and biotech strategy and startup experience. He currently advises several Artis portfolio companies including Unnatural Products and serves as the Interim CBO at Excision Biotherapeutics.

​

Pioneer Spotlight: Lessons from a biotech analyst and executive